

## Redeye Interview: Neola Medical Q2 2025 with CEO Hanna Sjöström

**In a new interview with Redeye's Gustaf Meyer, CEO Hanna Sjöström reflects on Q2 achievements and the road ahead. Redeye also provided a research update, raising their fair value range, now with a base case of SEK 3.3 (3.2).**

Watch the full interview here: [Redeye Interview: Neola Medical Q2 2025 with CEO Hanna Sjöström](#)

Access the research update and additional insights from Redeye here: <https://www.redeye.se/company/neola-medical>

### **For further information, contact:**

Hanna Sjöström, CEO

e-mail: [hanna.sjostrom@neolamedical.com](mailto:hanna.sjostrom@neolamedical.com)

### **About Neola Medical**

Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung complications in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on a spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola Medical builds on Sweden's longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at [www.neolamedical.com](http://www.neolamedical.com). The company's Certified Adviser is FNCA Sweden AB.

### **Image Attachments**

[Redeye Interview with CEO Hanna Sjöström following the Q2 report 2025](#)

### **Attachments**

[Redeye Interview: Neola Medical Q2 2025 with CEO Hanna Sjöström](#)